In comparison to an EZH2 selective inhibitor, higher anticancer activity were demonstrated against diffuse large B-cell lymphoma cells containing EZH2 gain-of-function mutations 133, 134. Here, EZH2 is linked to diffuse large B-cell lymphoma.